These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25482224)

  • 1. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.
    Chang MJ; Chae JW; Yun HY; Lee JI; Choi HD; Kim J; Park JS; Cho YJ; Yoon HI; Lee CT; Shin WG; Lee JH
    Tuberculosis (Edinb); 2015 Jan; 95(1):54-9. PubMed ID: 25482224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
    Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
    J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis.
    Jing Y; Zhu LQ; Yang JW; Huang SP; Wang Q; Zhang J
    J Clin Pharmacol; 2016 May; 56(5):622-7. PubMed ID: 26387492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV.
    Requena-Méndez A; Davies G; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DA
    Antimicrob Agents Chemother; 2012 May; 56(5):2357-63. PubMed ID: 22330931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
    Nijland HM; Ruslami R; Stalenhoef JE; Nelwan EJ; Alisjahbana B; Nelwan RH; van der Ven AJ; Danusantoso H; Aarnoutse RE; van Crevel R
    Clin Infect Dis; 2006 Oct; 43(7):848-54. PubMed ID: 16941365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
    Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
    J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
    Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.
    Medellín-Garibay SE; Cortez-Espinosa N; Milán-Segovia RC; Magaña-Aquino M; Vargas-Morales JM; González-Amaro R; Portales-Pérez DP; Romano-Moreno S
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7707-14. PubMed ID: 26438503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring in the treatment of tuberculosis patients.
    Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
    Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
    Wilkins JJ; Savic RM; Karlsson MO; Langdon G; McIlleron H; Pillai G; Smith PJ; Simonsson US
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2138-48. PubMed ID: 18391026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.
    Alisjahbana B; Sahiratmadja E; Nelwan EJ; Purwa AM; Ahmad Y; Ottenhoff TH; Nelwan RH; Parwati I; van der Meer JW; van Crevel R
    Clin Infect Dis; 2007 Aug; 45(4):428-35. PubMed ID: 17638189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels.
    Morehead RS
    South Med J; 2000 May; 93(5):507-10. PubMed ID: 10832953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China.
    Mi F; Tan S; Liang L; Harries AD; Hinderaker SG; Lin Y; Yue W; Chen X; Liang B; Gong F; Du J
    Trop Med Int Health; 2013 Nov; 18(11):1379-85. PubMed ID: 24112411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
    Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
    Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.
    Niward K; Ek Blom L; Davies Forsman L; Bruchfeld J; Eliasson E; Schön T; Chryssanthou E; Paues J
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
    Gurumurthy P; Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Padmapriyadarsini C; Swaminathan S; Venkatesan P; Sekar L; Kumar S; Krishnarajasekhar OR; Paramesh P
    Clin Infect Dis; 2004 Jan; 38(2):280-3. PubMed ID: 14699462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
    Gurumurthy P; Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Padmapriyadarsini C; Swaminathan S; Bhagavathy S; Venkatesan P; Sekar L; Mahilmaran A; Ravichandran N; Paramesh P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4473-5. PubMed ID: 15504887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.